HEMOSTEMIX INC (HEM.CA) Stock Price, Forecast & Analysis
TSX-V:HEM • CA4236943060
HEM.CA Key Statistics, Chart & Performance
The current stock price of HEM.CA is 0.085 CAD. In the past month the price decreased by -5.56%. In the past year, price decreased by -51.43%.
HEM.CA Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to HEM.CA. When comparing the yearly performance of all stocks, HEM.CA is a bad performer in the overall market: 93.54% of all stocks are doing better.
HEM.CA Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to HEM.CA. HEM.CA may be in some trouble as it scores bad on both profitability and health.
HEM.CA Financial Highlights
Over the last trailing twelve months HEM.CA reported a non-GAAP Earnings per Share(EPS) of -0.03. The EPS decreased by -36.36% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -253.72% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
HEM.CA Forecast & Estimates
HEM.CA Ownership
HEM.CA Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| EPRX | EUPRAXIA PHARMACEUTICALS INC | N/A | 580.689M | ||
| EDT | SPECTRAL MEDICAL INC | N/A | 400.807M | ||
| HBP | HELIX BIOPHARMA CORP | N/A | 152.76M | ||
| MDNA | MEDICENNA THERAPEUTICS CORP | N/A | 71.733M | ||
| COV | COVALON TECHNOLOGIES LTD | 12.94 | 44.192M | ||
| BCT | BRIACELL THERAPEUTICS CORP | N/A | 40.89M | ||
| MBX | MICROBIX BIOSYSTEMS INC | 5.94 | 33.252M | ||
| RVX | RESVERLOGIX CORP | N/A | 28.756M | ||
| MPH | MEDICURE INC | N/A | 11.693M |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the TSX Venture Exchange Exchange | Find stocks with similar TA and Setup ratings on the Canadian exchanges | Find stocks with similar Fundamental rating on the Canadian exchanges | Find the competitors with the best technical ratings on the Canadian exchanges | Find the competitors with the best fundamentals on the Canadian exchanges | Find the competitors with the best valuation on the Canadian exchanges | Find the competitors with the best dividend on the Canadian exchanges | Find the competitors with the best analyst ratings on the Canadian exchanges
About HEM.CA
Company Profile
Hemostemix, Inc. is a clinical-stage biotechnology company, which is focused on developing and commercializing a proprietary autologous cell therapy to treat ischemic diseases. The company is headquartered in Calgary, Alberta. The company went IPO on 2012-12-20. The firm has developed, patented, and is scaling and selling autologous (patient’s own) blood-based stem cell therapies that include angiogenic cell precursors (ACP-01), later neural cell precursors (NCP-01), and cardiomyocyte cell precursors (CCP-01). The company holds 91 patents on the derivation of three stem cell lineages from the patient’s blood, including ACP-01, CCP-01 and NCP-01. ACP-01 is a clinically relevant and statistically significant treatment for peripheral arterial disease, chronic limb-threatening ischemia, non-ischemic dilated cardiomyopathy, ischemic cardiomyopathy, congestive heart failure, and angina. The company has completed a Phase II clinical trial for chronic limb-threatening ischemia. The company has two wholly owned subsidiaries, Kwalata Trading Limited and PreCerv Inc. PreCerv Inc. holds a global field of use license to ACP-01 & NCP-01 for the treatment of conditions of the central and peripheral nervous system.
Company Info
HEMOSTEMIX INC
707 7th Ave. SW, Suite 1150
Calgary ALBERTA T2P 3H6 CA
CEO: Thomas Smeenk
Employees: 9
Phone: 19055804170
HEMOSTEMIX INC / HEM.CA FAQ
What does HEMOSTEMIX INC do?
Hemostemix, Inc. is a clinical-stage biotechnology company, which is focused on developing and commercializing a proprietary autologous cell therapy to treat ischemic diseases. The company is headquartered in Calgary, Alberta. The company went IPO on 2012-12-20. The firm has developed, patented, and is scaling and selling autologous (patient’s own) blood-based stem cell therapies that include angiogenic cell precursors (ACP-01), later neural cell precursors (NCP-01), and cardiomyocyte cell precursors (CCP-01). The company holds 91 patents on the derivation of three stem cell lineages from the patient’s blood, including ACP-01, CCP-01 and NCP-01. ACP-01 is a clinically relevant and statistically significant treatment for peripheral arterial disease, chronic limb-threatening ischemia, non-ischemic dilated cardiomyopathy, ischemic cardiomyopathy, congestive heart failure, and angina. The company has completed a Phase II clinical trial for chronic limb-threatening ischemia. The company has two wholly owned subsidiaries, Kwalata Trading Limited and PreCerv Inc. PreCerv Inc. holds a global field of use license to ACP-01 & NCP-01 for the treatment of conditions of the central and peripheral nervous system.
What is the stock price of HEMOSTEMIX INC today?
The current stock price of HEM.CA is 0.085 CAD.
Does HEMOSTEMIX INC pay dividends?
HEM.CA does not pay a dividend.
How is the ChartMill rating for HEMOSTEMIX INC?
HEM.CA has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
What is the Price/Earnings (PE) ratio of HEMOSTEMIX INC (HEM.CA)?
HEMOSTEMIX INC (HEM.CA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.03).